Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
Year: 2010
Type: article
DOI: 10.1038/ajg.2010.78
Institutions: Christian-Albrechts-Universität zu Kiel, University Hospital Schleswig-Holstein, Hôpital Claude Huriez, UCB Pharma (United Kingdom), University of Regensburg, Centro de Investigación Biomédica en Red, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Mayo Clinic
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: Abbott Laboratories, UCB Pharma
OpenAlex ID: W2017149988
